These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21503391)

  • 21. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.
    Miao Y; Yu-Jie Z; Zhi-Jian W; Dong-Mei S; Yu-Yang L; Ying-Xin Z; Fei G; Shi-Wei Y; De-An J
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):361-7. PubMed ID: 22419375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents.
    Choi DH; Park KW; Yang HM; Lee HY; Park JS; Kang HJ; Kim YJ; Koo BK; Oh BH; Park YB; Kim HS
    Int J Cardiol; 2011 Jun; 149(2):174-181. PubMed ID: 20138378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of bare-metal and drug-eluting stents in patients with chronic kidney disease (from the NHLBI Dynamic Registry).
    Green SM; Selzer F; Mulukutla SR; Tadajweski EJ; Green JA; Wilensky RL; Laskey WK; Cohen HA; Rao SV; Weisbord SD; Lee JS; Reis SE; Kip KE; Kelsey SF; Williams DO; Marroquin OC
    Am J Cardiol; 2011 Dec; 108(11):1658-64. PubMed ID: 21890077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year clinical outcomes following elective drug-eluting versus bare-metal stent implantation: results from a large single-center database.
    Gao RL; Xu B; Chen JL; Yang YJ; Qiao SB; Wang Y; Dou KF; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li W
    Chin Med J (Engl); 2009 Oct; 122(19):2261-7. PubMed ID: 20079124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between drug-eluting and bare metal stent on ST-elevation myocardial infarction outcome: should second-generation drug-eluting stent be preferred?
    Giglioli C; Cecchi E; Vladi L; Stolcova M; Valente S; Meucci F; Baldereschi GJ; Chiostri M; Romano SM; Gensini GF; Barchielli A; Balzi D
    J Cardiol; 2014 Apr; 63(4):296-301. PubMed ID: 24365386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era.
    Appleby CE; Ivanov J; Lavi S; Mackie K; Horlick EM; Ing D; Overgaard CB; Seidelin PH; von Harsdorf R; Dzavík V
    Circ Cardiovasc Interv; 2009 Aug; 2(4):309-16. PubMed ID: 20031733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.
    Jeong YH; Hong MK; Lee CW; Park DW; Kim YH; Kim JJ; Park SW; Park SJ
    Int J Cardiol; 2008 Mar; 125(1):36-40. PubMed ID: 17521753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of drug-eluting stent implantation for patients with multiple coronary chronic total occlusions.
    Zhang J; Han YL; Li Y; Wang SL; Jing QM; Wang XZ; Ma YY; Luan B; Wang G; Wang B
    Chin Med J (Engl); 2010 Apr; 123(7):789-93. PubMed ID: 20497665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
    Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
    Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentations and outcomes.
    Hayes KR; Applegate RJ; Sacrinty MT; Kutcher MA; Gandhi SK; Santos RM; Little WC
    J Invasive Cardiol; 2010 Jun; 22(6):266-70. PubMed ID: 20516505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of drug-eluting balloon in patients with bare-metal or drug-eluting stent restenosis.
    Berta B; Jambrik Z; Kohar K; Szabo G; Ruzsa Z; Molnar L; Barczi G; Geller L; Becker D; Merkely B
    Hellenic J Cardiol; 2014; 55(5):369-77. PubMed ID: 25243435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
    Garg P; Normand SL; Silbaugh TS; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Mauri L
    Circulation; 2008 Nov; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug eluting stents are superior to bare metal stents to reduce clinical outcome and stent-related complications in CKD patients, a systematic review, meta-analysis and network meta-analysis.
    Crimi G; Gritti V; Galiffa VA; Scotti V; Leonardi S; Ferrario M; Ferlini M; De Ferrari GM; Oltrona Visconti L; Klersy C
    J Interv Cardiol; 2018 Jun; 31(3):319-329. PubMed ID: 29285790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
    Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.